Nedbank
Financial Services • Sandton, South Africa
PROVIREX is a pioneering biotech company dedicated to developing groundbreaking genome editing therapies for the cure of HIV. They harness highly specific designer recombinases to precisely remove integrated hiv dna from infected cells. Their core technology harnesses highly specific designer recombinases to precisely remove integrated hiv dna from infected cells. unlike conventional gene editing methods, their recombinase-based approach
Headcount
0
10,001+ employees
Hiring
142
Open roles
Revenue Signal
$3.9B
Estimated annual revenue
Last Round
$0
Most recent funding amount